Kritikou P, Vadalouca A, Rekatsina M, Varrassi G, Siafaka I. The diagnostic odyssey of patients with chronic neuropathic pain-expert opinion of Greek pain specialists. Clin Pract. 2023;13(1):166–76. https://doi.org/10.3390/clinpract13010015.

Article  PubMed  PubMed Central  Google Scholar 

Di Stefano G, Di Lionardo A, Di Pietro G, Truini A. Neuropathic pain related to peripheral neuropathies according to the IASP grading system criteria. Brain Sci. 2020;11(1):1. https://doi.org/10.3390/brainsci11010001.

Article  PubMed  PubMed Central  Google Scholar 

Landolfo E, Cutuli D, Petrosini L, Caltagirone C. Effects of palmitoylethanolamide on neurodegenerative diseases: a review from rodents to humans. Biomolecules. 2022;12(5):667. https://doi.org/10.3390/biom12050667.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lang-Illievich K, Klivinyi C, Lasser C, Brenna CTA, Szilagyi IS, Bornemann-Cimenti H. Palmitoylethanolamide in the treatment of chronic pain: a systematic review and meta-analysis of double-blind randomized controlled trials. Nutrients. 2023;15(6):1350. https://doi.org/10.3390/nu15061350.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Assogna M, Di Lorenzo F, Martorana A, Koch G. Synaptic effects of palmitoylethanolamide in neurodegenerative disorders. Biomolecules. 2022;12(8):1161. https://doi.org/10.3390/biom12081161.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5. https://doi.org/10.1186/s41073-019-0064-8.

Article  PubMed  PubMed Central  Google Scholar 

Petrosino S, Schiano MA. Palmitoylethanolamide: a nutritional approach to keep neuroinflammation within physiological boundaries—a systematic review. Int J Mol Sci. 2020;21(24):9526. https://doi.org/10.3390/ijms21249526.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lang-Illievich K, Klivinyi C, Rumpold-Seitlinger G, Dorn C, Bornemann-Cimenti H. The effect of palmitoylethanolamide on pain intensity, central and peripheral sensitization, and pain modulation in healthy volunteers-a randomized, double-blinded, placebo-controlled crossover trial. Nutrients. 2022;14(19):4084. https://doi.org/10.3390/nu14194084.

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Amico R, Impellizzeri D, Cuzzocrea S, Di Paola R. ALIAmides update: palmitoylethanolamide and its formulations on management of peripheral neuropathic pain. Int J Mol Sci. 2020;21(15):5330. https://doi.org/10.3390/ijms21155330.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017;174(11):1349–65. https://doi.org/10.1111/bph.13580.

Article  CAS  PubMed  Google Scholar 

Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012;13(9):1121–30. https://doi.org/10.1111/j.1526-4637.2012.01432.x.

Article  PubMed  Google Scholar 

Lambert DM, Vandevoorde S, Diependaele G, Govaerts SJ, Robert AR. Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia. 2001;42(3):321–7. https://doi.org/10.1046/j.1528-1157.2001.41499.x.

Article  CAS  PubMed  Google Scholar 

Romero TR, Resende LC, Guzzo LS, Duarte ID. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesth Analg. 2013;116(2):463–72. https://doi.org/10.1213/ANE.0b013e3182707859.

Article  CAS  PubMed  Google Scholar 

Esposito E, Impellizzeri D, Mazzon E, Paterniti I, Cuzzocrea S. Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson’s disease. PLoS ONE. 2012;7(8): e41880. https://doi.org/10.1371/journal.pone.0041880.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmitz A, Anselme C, Ravallec M, Rebuf C, Simon JC, Gatti JL, Poirié M. The cellular immune response of the pea aphid to foreign intrusion and symbiotic challenge. PLoS ONE. 2012;7(7): e42114. https://doi.org/10.1371/journal.pone.0042114.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Phys. 2016;19(2):11–24 (PMID: 26815246).

Google Scholar 

Passavanti MB, Alfieri A, Pace MC, Pota V, Sansone P, Piccinno G, Barbarisi M, Aurilio C, Fiore M. Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review. Syst Rev. 2019;8(1):9. https://doi.org/10.1186/s13643-018-0934-z.

Article  PubMed  PubMed Central  Google Scholar 

Varrassi G, Fusco M, Skaper SD, Battelli D, Zis P, Coaccioli S, Pace MC, Paladini A. A pharmacological rationale to reduce the incidence of opioid-induced tolerance and hyperalgesia: a review. Pain Ther. 2018;7(1):59–75. https://doi.org/10.1007/s40122-018-0094-9.

Article  PubMed  PubMed Central  Google Scholar 

D’Aloia A, Molteni L, Gullo F, Bresciani E, Artusa V, Rizzi L, Ceriani M, Meanti R, Lecchi M, Coco S, Costa B, Torsello A. Palmitoylethanolamide modulation of microglia activation: characterization of mechanisms of action and implication for its neuroprotective effects. Int J Mol Sci. 2021;22(6):3054. https://doi.org/10.3390/ijms22063054.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skaper SD, Facci L, Giusti P. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol Neurobiol. 2013;48(2):340–52. https://doi.org/10.1007/s12035-013-8487-6.

Article  CAS  PubMed  Google Scholar 

De Icco R, Greco R, Demartini C, Vergobbi P, Zanaboni A, Tumelero E, Reggiani A, Realini N, Sances G, Grillo V, Allena M, Tassorelli C. Spinal nociceptive sensitization and plasma palmitoylethanolamide levels during experimentally induced migraine attacks. Pain. 2021;162(9):2376–85. https://doi.org/10.1097/j.pain.0000000000002223.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson’s disease. CNS Neurol Disord Drug Targets. 2017;16(6):705–13. https://doi.org/10.2174/1871527316666170321124949.

Article  CAS  PubMed  Google Scholar 

Cristiano C, Avagliano C, Cuozzo M, Liguori FM, Calignano A, Russo R. The beneficial effects of ultramicronized palmitoylethanolamide in the management of neuropathic pain and associated mood disorders induced by paclitaxel in mice. Biomolecules. 2022;12(8):1155. https://doi.org/10.3390/biom12081155.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Cesare ML, D’Agostino G, Pacini A, Russo R, Zanardelli M, Ghelardini C, Calignano A. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm. 2013;2013: 328797. https://doi.org/10.1155/2013/328797.

Article  CAS  Google Scholar 

Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G, Manzo I, Furiano A, Rizzo A, Imperatore R, Iannotti FA, D’Aniello E, Piscitelli F, Sca Rossi F, Cristino L, Di Marzo V, de Novellis V, Maione S. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017;7(1):375. https://doi.org/10.1038/s41598-017-00342-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noce A, Albanese M, Marrone G, Di Lauro M, Pietroboni Zaitseva A, Palazzetti D, Guerriero C, Paolino A, Pizzenti G, Di Daniele F, Romani A, D’Agostini C, Magrini A, Mercuri NB, Di Daniele N. Ultramicronized palmitoylethanolamide (um-PEA): a new possible adjuvant treatment in COVID-19 patients. Pharmaceuticals (Basel). 2021;14(4):336. https://doi.org/10.3390/ph14040336.

Article